TLR9 agonist CpG enhances protective nasal HSP60 peptide vaccine efficacy in experimental autoimmune arthritis

Zonneveld‐Huijssoon, Evelien; Wijk, Femke van; Roord, Sarah; Delemarre, Eveline M.; Meerding, Jenny; Jager, Wilco de; Klein, Mark; Albani, Salvatore; Kuis, Wietse; Boes, Marianne; Prakken, Berent J.

doi:10.1136/annrheumdis-2011-201131

Cited by 25 publications

(19 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus activation of pDCs through TLR9 is reported to be a normal, physiological response to DNA released in membrane microparticles from apoptotic cells (1553). CpG ODNs able to activate Th1 responses in some settings may also promote immune tolerance through Treg with enhanced IL-10 production in other contexts (541,2122). Perhaps further understanding of these complexities may help explain why in another study, depletion of pDC using a different anti-BST2 antibody was reported to increase carotid atherosclerosis induced by colar placement in LDLR null mice.…”

Section: Neutrophils May Interact With Plasmacytoid Dcs To Enhance Atmentioning

confidence: 99%

Molecular Biology of Atherosclerosis

Hopkins

2013

Physiological Reviews

382

344

View full text Add to dashboard Cite

At least 468 individual genes have been manipulated by molecular methods to study their effects on the initiation, promotion, and progression of atherosclerosis. Most clinicians and many investigators, even in related disciplines, find many of these genes and the related pathways entirely foreign. Medical schools generally do not attempt to incorporate the relevant molecular biology into their curriculum. A number of key signaling pathways are highly relevant to atherogenesis and are presented to provide a context for the gene manipulations summarized herein. The pathways include the following: the insulin receptor (and other receptor tyrosine kinases); Ras and MAPK activation; TNF-␣ and related family members leading to activation of NF-B; effects of reactive oxygen species (ROS) on signaling; endothelial adaptations to flow including G protein-coupled receptor (GPCR) and integrin-related signaling; activation of endothelial and other cells by modified lipoproteins; purinergic signaling; control of leukocyte adhesion to endothelium, migration, and further activation; foam cell formation; and macrophage and vascular smooth muscle cell signaling related to proliferation, efferocytosis, and apoptosis. This review is intended primarily as an introduction to these key signaling pathways. They have become the focus of modern atherosclerosis research and will undoubtedly provide a rich resource for future innovation toward intervention and prevention of the number one cause of death in the modern world.

show abstract

Section: Neutrophils May Interact With Plasmacytoid Dcs To Enhance Atmentioning

confidence: 99%

Molecular Biology of Atherosclerosis

Hopkins

2013

Physiological Reviews

382

344

View full text Add to dashboard Cite

show abstract

“…Specifically, M cells in Peyer's patches take up luminal antigens to be presented to naive T cells in a controlled manner, which promotes their differentiation into a regulatory function . Thus, induction of adequate mucosal tolerance requires both colonization of beneficial microbes and interplay between innate and adaptive arms of the immune system and based on experimental studies, failure in this maturation process can predispose to autoantibody formation and arthritis…”

Section: The Microbiota and Immunologic Maturationmentioning

confidence: 99%

Microbial orchestra in juvenile idiopathic arthritis: Sounds of disarray?

Arvonen

Vänni

Sarangi

et al. 2019

Immunological Reviews

View full text Add to dashboard Cite

The role of the microbiota in multiple autoimmune diseases, including juvenile idiopathic arthritis (JIA) has earned substantial attention in the last 10 years. Increasing evidence suggests that the microbiota's link to JIA begins in early childhood, as early life events that influence the nature of the microbiota also appear to influence disease risk. In this review, we discuss these early life events including mode of delivery, infant feeding practice, antibiotics exposure, and other events and their impacts on the microbiota and on disease risk; reported abnormalities of the microbiota in children with JIA; mechanisms by which an altered microbiota at birth and later on in childhood may influence disease risk; and the prospects for therapeutic alteration of the microbiota in children with JIA.

show abstract

“…The hydrogel contained PLGA microparticles encapsulating denatured insulin to promote self-tolerance to recruited DCs and, notably, CpG. While CpG is more classically used as a vaccine adjuvant in an inflammatory capacity, the authors note it can elicit anti-inflammatory effects such as inducing IL-10 production [106]. This approach protected disease incidence in 40% of pre-diabetic mice.…”

Section: Controlled-release Approaches To Recruit Immune Cellsmentioning

confidence: 99%

Combinatorial drug delivery approaches for immunomodulation

Stewart

Keselowsky

2017

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Immunotherapy has been widely explored for applications to both augment and suppress intrinsic host immunity. Clinical achievements have seen a number of immunotherapeutic drugs displace established strategies like chemotherapy in treating immune-associated diseases. However, single drug approaches modulating an individual arm of the immune system are often incompletely effective. Imperfect mechanistic understanding and heterogeneity within disease pathology have seen monotherapies inadequately equipped to mediate complete disease remission. Recent success in applications of combinatorial immunotherapy has suggested that targeting multiple biological pathways simultaneously may be critical in treating complex immune pathologies. Drug delivery approaches through engineered biomaterials offer the potential to augment desired immune responses while mitigating toxic side-effects by localizing immunotherapy. This review discusses recent advances in immunotherapy and highlights newly explored combinatorial drug delivery approaches. Furthermore, prospective future directions for immunomodulatory drug delivery to exploit are provided.

show abstract

TLR9 agonist CpG enhances protective nasal HSP60 peptide vaccine efficacy in experimental autoimmune arthritis

Abstract: These clinical and immunological data suggest the use of CpG as a potent adjuvant for mucosal peptide-specific immune therapy in arthritis.

Cited by 25 publications

References 82 publications

Molecular Biology of Atherosclerosis

Molecular Biology of Atherosclerosis

Microbial orchestra in juvenile idiopathic arthritis: Sounds of disarray?

Combinatorial drug delivery approaches for immunomodulation

Contact Info

Product

Resources

About